In 2 phase II open-label clinical trials, the combination of ABT-493 (NS3/4A protease inhibitor) plus ABT-530 (NS5A inhibitor) achieved sustained virologic response in 96%-100% of patients with HCV genotype 1 or 3 infection and compensated cirrhosis.